AE
OBIO icon

AMH Equity’s Orchestra BioMed OBIO Stock Holding History

AMH Equity’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$412K Buy
+166,000
New +$458K 0.51% 46

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AMH Equity's OBIO Position: Q3 2025 in Review

AMH Equity opened a new position in Orchestra BioMed (OBIO) in Q3 2025: 166,000 shares worth $412K. The stake represents 0.51% of the portfolio and ranks #46 among its holdings.

52 funds tracked by Wall St. Rank hold OBIO as of Q3 2025.

  • AMH Equity held 166,000 shares of Orchestra BioMed worth $412K as of Q3 2025.
  • Orchestra BioMed was a new AMH Equity position in Q3 2025.
  • Orchestra BioMed made up 0.51% of AMH Equity's portfolio in Q3 2025, its #46 holding.
  • 52 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2025.

Based on AMH Equity's 13F filing for Q3 2025, filed 29 Oct 2025.